drugset / Trial / NCT06797401

Phase 2 Trial Evaluating the Efficacy and Safety of RBD5044 in Patients With Mixed Dyslipidemia

NCT06797401 ↗

Phase 2 Recruiting 120 enrolled Ribocure Pharmaceuticals AB
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The goal of this clinical trial is to learn if drug RBD5044 works to treat mixed dyslipidemia in adults. It will also learn about the safety of drug RBD5044. The main questions it aims to answer are: Does drug RBD5044 reduce the triglyceride levels? What medical problems may participants experience when taking drug RBD5044? Researchers will compare drug RBD5044 to a placebo to see if drug RBD5044 works to treat mixed dyslipidemia. Participants will: Receive RBD5044 or placebo twice during the trial (Day 1 and Day 84). Visit the clinic 11 times during 12 months (visit every 4-8 weeks) for checkups and tests.

Timeline

Start
2025-01-28
Primary completion
2026-05-31
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject RBD5044 Unknown — Subcutaneous

Indications